Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Rhea-AI Summary
Protara Therapeutics (Nasdaq:TARA), a clinical-stage biotech developing therapies for cancer and rare diseases, will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on May 26, 2026 at 9:30 a.m. ET. The live webcast and a limited-time archive will be available in the Events and Presentations section of Protara’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – TARA
In the May 20 session, TARA gained 9.68%, reflecting a notable positive market reaction. Argus tracked a peak move of +10.9% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 18 | Investor webinar | Neutral | -9.8% | Announced investor webinar focused on TARA-002 in lymphatic malformations. |
| May 15 | Clinical data update | Positive | -3.8% | Reported durable 12-month complete responses in Phase 2 ADVANCED-2 BCG-naïve cohort. |
| May 13 | Earnings results | Positive | +1.0% | Q1 2026 results with $177.4M cash and clear TARA-002 development timelines. |
| Apr 27 | Conference presentation | Neutral | +1.4% | Planned presentation of updated interim 12‑month ADVANCED-2 data at AUA meeting. |
| Mar 10 | Earnings results | Positive | -0.7% | FY 2025 update with promising ADVANCED‑2 data and cash of about $197.9M. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive and clinical updates often saw flat-to-negative next-day reactions, suggesting a tendency for muted or contrarian trading around news.
Over the last six months, TARA has reported multiple clinical and financial milestones, including updated ADVANCED-2 data, cash of $177.4M funding operations into 2028, and repeat earnings updates. Even positive clinical results and data presentations sometimes preceded modest declines, while one earnings update saw a small gain. Today’s conference participation headline fits a pattern of frequent communications around TARA‑002 and broader oncology visibility rather than a discrete value-defining catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Tuesday, May 26, 2026, at 9:30 am ET.
A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
